• Users Online: 86
  • Print this page
  • Email this page
Year : 2017  |  Volume : 7  |  Issue : 2  |  Page : 70-76

Management of macular edema due to central retinal vein occlusion – The role of aflibercept

1 Associated Retinal Consultants, Michigan, USA
2 University of Nebraska Medical School, Omaha, Nebraska, USA
3 Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA

Correspondence Address:
Diana V Do
Professor of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Palo Alto, California
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjo.tjo_9_17

Rights and Permissions

Central retinal vein occlusion (CRVO) can cause vision loss. The pathogenesis of CRVO involves a thrombus formation leading to increased retinal capillary pressure, increased vascular permeability, and possibly retinal neovascularization. Vision loss due to CRVO is commonly caused by macular edema. Multiple treatment modalities have been used to treat macular edema. Currently, the most common therapy used is intravitreal inhibition of vascular endothelial growth factor (VEGF). The three most widely used agents are aflibercept, bevacizumab, and ranibizumab and they are effective at blocking VEGF. In addition, intraocular steroids can be used to treat macular edema. This review will briefly cover the treatment options and discuss in greater detail the efficacy and safety of aflibercept.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded400    
    Comments [Add]    
    Cited by others 6    

Recommend this journal